ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Exonate launches diabetic macular oedema trial pharmatimes
February 04, 2021Cambridge, UK-based Exonate has dose the first patient with its lead compound – EXN 407 – in a Phase Ib/II clinical trial investigating the drug in volunteers with centre-involved diabetic macular oedema (CI-DMO).
Pharma Sources Insight July 2025
